Crossmark

Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur

Crossref DOI link: https://doi.org/10.1007/s00198-017-4286-7

Published Online: 2017-10-30

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Greenspan, S. L.

Vujevich, K.

Britton, C.

Herradura, A.

Gruen, G.

Tarkin, I.

Siska, P.

Hamlin, B.

Perera, S.
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2017-10-30
More Information

Article History

Received: 27 March 2017

Accepted: 25 October 2017

First Online: 30 October 2017

Compliance with ethical standards

:

: Dr. Greenspan has received research grants from Eli Lilly and Amgen; Drs. Britton, Herradura, Gruen, Tarkin, Siska, Hamlin, Perera, and K. Vujevich have no disclosures.